The week in pharma: action, reaction and insight – week to February 2, 2024
By Barbara Obstoj-Cardwell. Editor
Among important clinical trial news last week, US pharma giant Merck & Co released positive new data on its PD-1 therapy Keytruda (pembrolizumab) in the treatment of bladder cancer. Also, Vertex Pharmaceuticals reported encouraging new data on its non-opioid acute pain candidate VX-548. On the deal-making front, Austria’s Hookipa Pharma announced that Swiss giant Roche is terminating its collaboration on the HB-700 program in KRAS mutated cancer, as a result of which Hookipa is reprioritizing its focus. Among the fourth-quarter and full-year 2023 financial results that were released last week, Merck & Co’s pruning of its R&D pipeline attracted comment.
Pembro breaks through the ccRCC OS barrier
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze